Search

Your search keyword '"Giamarellos-Bourboulis, Evangelos J"' showing total 1,733 results

Search Constraints

Start Over You searched for: Author "Giamarellos-Bourboulis, Evangelos J" Remove constraint Author: "Giamarellos-Bourboulis, Evangelos J"
1,733 results on '"Giamarellos-Bourboulis, Evangelos J"'

Search Results

1. The pathophysiology of sepsis and precision-medicine-based immunotherapy

2. Developing a Tool for Differentiation Between Bacterial and Viral Respiratory Infections Using Myxovirus Resistance Protein A and C-Reactive Protein

4. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study*

6. Fatty acid desaturation and lipoxygenase pathways support trained immunity

7. Immune responses of patients on maintenance hemodialysis after infection by SARS-CoV-2: a prospective observational cohort study

10. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

12. HEPARIN-BINDING PROTEIN LEVELS PREDICT UNFAVORABLE OUTCOME IN COVID-19 PNEUMONIA: A POST HOC ANALYSIS OF THE SAVE TRIAL

13. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

14. Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial

15. Performance evaluation of a PCR panel (FilmArray® Pneumonia Plus) for detection of respiratory bacterial pathogens in respiratory specimens: A systematic review and meta-analysis

16. A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019

18. Towards personalized medicine: a scoping review of immunotherapy in sepsis

19. Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

20. qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial

23. Dimethyl itaconate induces long-term innate immune responses and confers protection against infection

25. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI

26. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

27. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

28. Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial

29. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial

30. Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial etiology

31. Redefining critical illness

32. A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece

34. From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations For Developing Precision Medicine in ICU

36. Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II

39. Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial

41. A 6-mRNA host response classifier in whole blood predicts outcomes in COVID-19 and other acute viral infections

42. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial

44. Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure

45. Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial

46. Author Correction: Transmission of trained immunity and heterologous resistance to infections across generations

47. From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations for Developing Precision Medicine in the ICU.

48. Transmission of trained immunity and heterologous resistance to infections across generations

49. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Catalog

Books, media, physical & digital resources